- Home
- LNTH vs DLB Comparison
LNTH vs DLB Comparison
Compare LNTH & DLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNTH | DLB |
|---|---|---|
| Founded | 1956 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Multi-Sector Companies |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 6.4B |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LNTH | DLB |
|---|---|---|
| Price | $69.61 | $64.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $78.00 | ★ $93.60 |
| AVG Volume (30 Days) | ★ 1.1M | 602.7K |
| Earning Date | 02-25-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 2.26% |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.39 | ★ 2.62 |
| Revenue | ★ $1,525,933,000.00 | $1,349,130,000.00 |
| Revenue This Year | $0.01 | $5.03 |
| Revenue Next Year | $0.52 | $4.02 |
| P/E Ratio | $28.83 | ★ $24.37 |
| Revenue Growth | 1.95 | ★ 5.92 |
| 52 Week Low | $47.25 | $63.23 |
| 52 Week High | $111.29 | $89.66 |
Technical Indicators
Market Signals| Indicator | LNTH | DLB |
|---|---|---|
| Relative Strength Index (RSI) | 71.09 | 42.02 |
| Support Level | $66.36 | $63.23 |
| Resistance Level | $67.45 | $66.34 |
| Average True Range (ATR) | 1.69 | 1.04 |
| MACD | -0.01 | -0.25 |
| Stochastic Oscillator | 93.81 | 34.33 |
Price Performance
Historical ComparisonAbout LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About DLB Dolby Laboratories
Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.